Miltenyi Bioindustry division to supply commercial-ready lentiviral vector to support clinical development of PRAME cell therapy
Bergisch Gladbach, October 16, 2025 – Miltenyi Biotec, a global leader innovating technologies and services for patient-specific cell and gene therapies, today announced it has entered into a commercial supply agreement with Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME.
Under the terms of the agreement, Miltenyi Biotec will provide, through its dedicated CDMO division Miltenyi Bioindustry, commercial manufacturing and supply services of lentiviral vectors for Immatics’ lead adoptive cell therapy product candidate, anzu-cel (anzutresgene autoleucel, IMA203). This collaboration builds on the long-lasting partnership between the two companies and supports the potential commercialization of anzu-cel, currently in Phase III clinical development. The aim is to provide the lentiviral vector for Immatics’ manufacturing of a scalable, GMP-compliant, PRAME-targeted, TCR T-cell therapy product for future commercial supply at Immatics’ manufacturing site in the greater Houston area, TX.
Miltenyi Bioindustry’s site in Gaithersburg, MD, received FDA approval to manufacture commercial lentiviral vector in 2024. This center of excellence for viral vector development has manufactured over 400 batches of 50L and 200L serum-free suspension GMP-grade lentiviral vector to support over 100 clinical trials in 55 countries.
Dr. Boris Stoffel, Managing Director and Member of the Executive Board at Miltenyi Biotec, said: “We are proud to support Immatics as they advance to bring anzu-cel to the market. This agreement underscores our commitment to enabling innovative cell and gene therapies to reach patients worldwide.”
Dr. Steffen Walter, Chief Operating Officer of Immatics, said: “Miltenyi Biotec’s proven expertise and capabilities, anchored in its Miltenyi Bioindustry division, are instrumental in ensuring our scalable, high-quality manufacturing of anzu-cel as we prepare for commercialization. We are excited to continue working closely with Miltenyi Biotec to bring meaningful benefit to patients with PRAME cancers.”
About Miltenyi Biotec
Miltenyi Biotec is a global leader innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,700 employees across 24 countries.
Go to www.miltenyibiotec.com or follow Miltenyi Biotec on LinkedIn and X to get the latest updates.
Media contact
Kim Münster
Miltenyi Biotec, Corporate Communications
[email protected]